Screener
PTC Therapeutics PTCT Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Deferred income taxes | (10) | 2 |
| Amortization of discounts on investments, net | (4,114) | (2,313) |
| Amortization of debt issuance costs | 305 | 299 |
| Share-based compensation expense | 23,421 | 18,060 |
| Unrealized foreign currency transaction losses, net | (887) | 2,251 |
| Changes in operating assets and liabilities: | ||
| Inventory, net | 2,643 | 2,191 |
| Prepaid expenses and other current assets | 1,180 | (16,429) |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's stock-based comp?
- PTC Therapeutics (PTCT) reported stock-based comp of $23.42M in Q1 2026.
- How has PTC Therapeutics's stock-based comp changed year-over-year?
- PTC Therapeutics's stock-based comp increased by 29.7% year-over-year, from $18.06M to $23.42M.
- What is the long-term trend for PTC Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), PTC Therapeutics's stock-based comp has grown at a -7.9% compound annual growth rate (CAGR), from $103.51M to $74.55M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about PTC Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude